Maravai LifeSciences Completes Acquisition of Officinae Bio’s DNA and RNA Business

• Maravai LifeSciences has completed the acquisition of Officinae Bio’s DNA and RNA business, expanding its presence into Europe.

• The deal integrates Officinae Bio’s AI-driven mRNA design with Maravai and TriLink BioTechnologies’ drug substance manufacturing capabilities.

Maravai LifeSciences has officially completed its acquisition of Officinae Bio’s DNA and RNA business, expanding its expertise in mRNA design and drug substance manufacturing. The deal integrates Officinae Bio’s AI-enabled mRNA sequence-optimization platform with Maravai and its subsidiary TriLink BioTechnologies‘ manufacturing capabilities, supporting a streamlined transition from mRNA design to clinical development and commercial production.

Based in Venice, Italy, Officinae Bio’s proprietary digital platform accelerates mRNA drug candidate prototyping by allowing researchers to test various capping analogs, chemical modifications, and sequence designs. This capability enhances the efficiency of moving mRNA-based therapies into clinical trials.

Trey Martin, CEO of Maravai LifeSciences, emphasized the significance of the acquisition, stating, “We are thrilled to bring Officinae into the Maravai family, where their talented team will add cutting-edge AI-driven sequence design and seamless e-commerce to our TriLink Discovery business. This acquisition also marks our first move into the very important European marketplace with a manufacturing footprint.”

Davide De Lucrezia, CEO and co-founder of Officinae Bio, will continue leading the business within Maravai’s Nucleic Acid Production segment. He noted that the acquisition will enable Officinae Bio to extend its AI-driven tools to more customers and improve candidate sequence identification, while leveraging TriLink’s decades of experience in chemical and biological manufacturing.